NutraGenesis Receives U.S. PatentNutraGenesis Receives U.S. Patent
The U.S. Patent and Trademark Office has issued NutraGenesis a patent covering its WellBody 365® nutraceutical ingredient, a combination of beta glucan and ashwagandha.
January 7, 2014
BRATTLEBORO, Vt.The U.S. Patent and Trademark Office has issued NutraGenesis a patent covering its WellBody 365® nutraceutical ingredient, a combination of beta glucan and ashwagandha. The patent covers the composition that enhances immune activity during chronic stress by increasing cytokines and phagocytosis, NutraGenesis said. The ingredient contains a clinically tested, multi-patented immunomodulating Maitake mushroom extract with the standardized ashwagandha extract Sensoril®.
WellBody 365® represents a departure from traditional immune-modulators that simply address immune support," said company president and managing director Suzanne McNeary. "Patented WellBody 365® is the next-generation immune nutraceutical that provides immune modulation as well as dramatic resistance to stress for broad spectrum, daily support and protection of immune function."
You May Also Like
The rise of ashwagandha: A case study in a growing and evolving category – articleNov 28, 2023
Ashwagandha: Roots for wellness, leaves for soil – articleNov 28, 2023
Creatine, whey protein, beta-alanine among picks in NFL-style draft at SupplySide WestDec 01, 2023
Unleash the power of ‘combos’ supplements to meet consumer demand – infographicNov 22, 2023